Posted by Michael Wonder on 10 Dec 2024
New price deal paves way for NICE approval of treatment for rare genetic condition
10 December 2024 - A new treatment for Duchenne muscular dystrophy is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
Vamorolone (Agamree, Santhera Pharmaceuticals), is an alternative to currently available corticosteroids used to reduce muscle inflammation and maintain muscle strength and function in patients with Duchenne muscular dystrophy.
